BRPI0511433A - derivados de quinolina substituìda como inibidores de cinesina mitótica - Google Patents
derivados de quinolina substituìda como inibidores de cinesina mitóticaInfo
- Publication number
- BRPI0511433A BRPI0511433A BRPI0511433-0A BRPI0511433A BRPI0511433A BR PI0511433 A BRPI0511433 A BR PI0511433A BR PI0511433 A BRPI0511433 A BR PI0511433A BR PI0511433 A BRPI0511433 A BR PI0511433A
- Authority
- BR
- Brazil
- Prior art keywords
- substituted quinoline
- quinoline derivatives
- mitotic kinesin
- kinesin inhibitors
- compounds
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 102000010638 Kinesin Human genes 0.000 title 1
- 108010063296 Kinesin Proteins 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000000394 mitotic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57312004P | 2004-05-21 | 2004-05-21 | |
| PCT/US2005/017961 WO2005113507A1 (en) | 2004-05-21 | 2005-05-19 | Substituted quinoline derivatives as mitotic kinesin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511433A true BRPI0511433A (pt) | 2007-12-11 |
Family
ID=34970815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511433-0A BRPI0511433A (pt) | 2004-05-21 | 2005-05-19 | derivados de quinolina substituìda como inibidores de cinesina mitótica |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7452996B2 (enExample) |
| EP (1) | EP1753723B1 (enExample) |
| JP (1) | JP2008502721A (enExample) |
| CN (1) | CN1956960A (enExample) |
| AT (1) | ATE404536T1 (enExample) |
| AU (1) | AU2005245492A1 (enExample) |
| BR (1) | BRPI0511433A (enExample) |
| CA (1) | CA2564215A1 (enExample) |
| DE (1) | DE602005008953D1 (enExample) |
| DK (1) | DK1753723T3 (enExample) |
| ES (1) | ES2311992T3 (enExample) |
| HR (1) | HRP20080493T3 (enExample) |
| MX (1) | MXPA06011958A (enExample) |
| PL (1) | PL1753723T3 (enExample) |
| PT (1) | PT1753723E (enExample) |
| RS (1) | RS50670B (enExample) |
| RU (1) | RU2385867C2 (enExample) |
| SI (1) | SI1753723T1 (enExample) |
| WO (1) | WO2005113507A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0511433A (pt) * | 2004-05-21 | 2007-12-11 | Chiron Corp | derivados de quinolina substituìda como inibidores de cinesina mitótica |
| AU2005273705B8 (en) | 2004-08-18 | 2010-01-28 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP3095456A1 (en) * | 2005-11-04 | 2016-11-23 | Glaxosmithkline LLC | Methods for administering hypoglycemic agents |
| BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
| CA2668661A1 (en) * | 2006-11-13 | 2008-05-29 | Novartis Ag | Substituted pyrazole and triazole compounds as ksp inhibitors |
| MX2009007260A (es) * | 2007-01-05 | 2009-07-10 | Novartis Ag | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5). |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| US8748626B2 (en) * | 2010-04-15 | 2014-06-10 | Novartis Ag | Oxazole and thiazole compounds as KSP inhibitors |
| AU2011239977B2 (en) * | 2010-04-15 | 2014-11-27 | Novartis Ag | Triazole compounds as KSP inhibitors |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
| US9458161B1 (en) | 2011-11-03 | 2016-10-04 | Vanderblit University | TSPO ligands for cancer imaging and treatment |
| NZ631362A (en) * | 2012-08-13 | 2016-09-30 | Array Biopharma Inc | Arry-520 for use in treating cancer in a patient with low aag |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| KR20250024102A (ko) | 2015-02-25 | 2025-02-18 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| RU2728932C2 (ru) * | 2015-08-19 | 2020-08-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения рака желчевыводящих путей |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| US20200197384A1 (en) | 2017-05-16 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172087B1 (en) * | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
| EP1165519A1 (en) | 1999-04-02 | 2002-01-02 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| DE60028227T2 (de) | 1999-10-27 | 2007-03-29 | Cytokinetics, Inc., South San Francisco | Chinazolinone benutzende verfahren und zusammenstellungen |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| AU2001296799A1 (en) | 2000-10-06 | 2002-04-15 | Neurogen Corporation | Benzimidazole and indole derivatives as crf receptor modulators |
| KR100883184B1 (ko) | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | Ｃｘｃｒ3 길항제 |
| EP1351671A1 (en) | 2001-01-19 | 2003-10-15 | Cytokinetics, Inc. | Triphenylmethane kinesin inhibitors |
| EP1360180A1 (en) | 2001-01-19 | 2003-11-12 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
| WO2003039460A2 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US6753428B2 (en) | 2001-11-20 | 2004-06-22 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| WO2003049527A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7244723B2 (en) | 2001-12-06 | 2007-07-17 | Merck & Co., Inc. | Substituted furopyrimidinones as a mitotic kinesin inhibitors |
| DE60222302T2 (de) | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
| EP1481077B1 (en) | 2001-12-06 | 2009-11-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| EP1551812B1 (en) | 2001-12-06 | 2009-03-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2003059289A2 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| CA2475879A1 (en) | 2002-02-15 | 2003-08-28 | Cytokinetics, Inc. | Synthesis of quinazolinones |
| AU2003249597B2 (en) | 2002-03-08 | 2007-06-28 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| PL211300B1 (pl) | 2002-04-17 | 2012-05-31 | Cytokinetics Inc | Związek i kompozycja zawierająca ten związek |
| WO2003094839A2 (en) | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
| AU2003270015A1 (en) | 2002-05-09 | 2003-12-02 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1513820A4 (en) | 2002-05-23 | 2006-09-13 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| EP1509507A4 (en) | 2002-05-23 | 2006-09-13 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| PL374190A1 (en) | 2002-06-14 | 2005-10-03 | Merck & Co, Inc. | Mitotic kinesin inhibitors |
| AU2003236527A1 (en) | 2002-06-14 | 2003-12-31 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1515949B1 (en) | 2002-06-14 | 2007-03-14 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2005537257A (ja) | 2002-07-08 | 2005-12-08 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン結合部位 |
| EP1539727B1 (en) | 2002-07-17 | 2009-02-18 | Cytokinetics, Inc. | Compounds, compositions, and methods for treating cellular proliferative diseases |
| EP1537089A4 (en) | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | CONNECTIONS, COMPOSITIONS AND PROCEDURES |
| EP1539180A4 (en) | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| JP2005539062A (ja) | 2002-09-13 | 2005-12-22 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| BRPI0511433A (pt) * | 2004-05-21 | 2007-12-11 | Chiron Corp | derivados de quinolina substituìda como inibidores de cinesina mitótica |
-
2005
- 2005-05-19 BR BRPI0511433-0A patent/BRPI0511433A/pt not_active IP Right Cessation
- 2005-05-19 RS RSP-2008/0534A patent/RS50670B/sr unknown
- 2005-05-19 PT PT05752901T patent/PT1753723E/pt unknown
- 2005-05-19 PL PL05752901T patent/PL1753723T3/pl unknown
- 2005-05-19 ES ES05752901T patent/ES2311992T3/es not_active Expired - Lifetime
- 2005-05-19 US US11/133,509 patent/US7452996B2/en not_active Expired - Fee Related
- 2005-05-19 JP JP2007527522A patent/JP2008502721A/ja active Pending
- 2005-05-19 SI SI200530384T patent/SI1753723T1/sl unknown
- 2005-05-19 CN CNA2005800164405A patent/CN1956960A/zh active Pending
- 2005-05-19 WO PCT/US2005/017961 patent/WO2005113507A1/en not_active Ceased
- 2005-05-19 DK DK05752901T patent/DK1753723T3/da active
- 2005-05-19 MX MXPA06011958A patent/MXPA06011958A/es active IP Right Grant
- 2005-05-19 HR HR20080493T patent/HRP20080493T3/xx unknown
- 2005-05-19 DE DE602005008953T patent/DE602005008953D1/de not_active Expired - Lifetime
- 2005-05-19 AU AU2005245492A patent/AU2005245492A1/en not_active Abandoned
- 2005-05-19 EP EP05752901A patent/EP1753723B1/en not_active Expired - Lifetime
- 2005-05-19 AT AT05752901T patent/ATE404536T1/de not_active IP Right Cessation
- 2005-05-19 RU RU2006145336/04A patent/RU2385867C2/ru not_active IP Right Cessation
- 2005-05-19 CA CA002564215A patent/CA2564215A1/en not_active Abandoned
-
2008
- 2008-09-30 US US12/242,360 patent/US20090028858A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1956960A (zh) | 2007-05-02 |
| PL1753723T3 (pl) | 2009-01-30 |
| WO2005113507A1 (en) | 2005-12-01 |
| JP2008502721A (ja) | 2008-01-31 |
| ATE404536T1 (de) | 2008-08-15 |
| US20090028858A1 (en) | 2009-01-29 |
| EP1753723B1 (en) | 2008-08-13 |
| DK1753723T3 (da) | 2008-10-20 |
| RS50670B (sr) | 2010-06-30 |
| CA2564215A1 (en) | 2005-12-01 |
| AU2005245492A1 (en) | 2005-12-01 |
| US20050261337A1 (en) | 2005-11-24 |
| RU2385867C2 (ru) | 2010-04-10 |
| ES2311992T3 (es) | 2009-02-16 |
| SI1753723T1 (sl) | 2009-04-30 |
| PT1753723E (pt) | 2008-11-19 |
| EP1753723A1 (en) | 2007-02-21 |
| MXPA06011958A (es) | 2006-12-15 |
| DE602005008953D1 (de) | 2008-09-25 |
| HRP20080493T3 (hr) | 2009-02-28 |
| US7452996B2 (en) | 2008-11-18 |
| RU2006145336A (ru) | 2008-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511433A (pt) | derivados de quinolina substituìda como inibidores de cinesina mitótica | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| MX2007004699A (es) | Derivados de indol y bencimidazol. | |
| MX2009007260A (es) | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5). | |
| PH12012500903A1 (en) | N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
| MX2013004733A (es) | Inhibidores de n1/n2-lactama acetil-coa carboxilasa. | |
| TW200801000A (en) | Spiroindolinone derivatives | |
| TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
| ATE495176T1 (de) | Spiroindolinon-derivate | |
| MX2012009186A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| MD20140124A2 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
| ATE517882T1 (de) | Chinolinderivate | |
| PH12013501941A1 (en) | Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors | |
| EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
| PA8821301A1 (es) | Inhibidores a base de hidroxamato de desacetilasas b | |
| TW200800951A (en) | Substituted imidazole compounds as KSP inhibitors | |
| DE602007011434D1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| ATE546448T1 (de) | Urotensin-ii-rezeptorantagonisten | |
| MX2009002606A (es) | Derivados de arginina con actividad antagonistica de np-1. | |
| EA200901085A1 (ru) | Производные циклогексиламида арилкарбоновой кислоты | |
| TR201901937T4 (tr) | 8-metil-1-fenil-imidazol[1,5-a]pirazin bileşikleri. | |
| UA92282C2 (ru) | 2-оксо-1,2-дигидрохинолин-з-карбоновые кислоты, которые проявляют анальгетическую активность |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) Free format text: ALTERADO DE: CHIRON CORPORATION |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |